Month: February 2022

Recce Pharmaceuticals Announces Final Subjects Dosed in Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and...

Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional ClassSOUTH SAN FRANCISCO,...

error: Content is protected !!